[Is it possible to stop nucleos(t)ide analogue based therapy in chronic hepatitis B?]

Date publication

janvier 2008

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre

Tous les auteurs :
Bronowicki JP, Nani A, Barraud H, Cadranel JF

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/18662610

Résumé

Nucleos(t)ide analogues are very efficient in the treatment of chronic hepatitis B. In the HBe antigen positive patients, the HBe seroconversion rates range from 12 to 22% after one year of treatment. When HBe seroconversion occure, it is possible to stop the treatment with analogue but only in non cirrhotic patients. If the treatment with analogue is continued for at least 6 months after confirmed HBeAg seroconversion, the HBe seroconversion is durable in 70-90% of patients. The follow up should be done during years. Stopping the treatment is more problematic in HBe antigen negative patients. A virological relapse occur in 44 to 80% of cases and a biochemical relapse occur in 30 to 70% of cases. Stopping the treatment with an analogue in this population should be considered only in a prospective study with careful monitoring and with a long term follow up.

Référence

Gastroenterol Clin Biol. 2008 Jan;32(1 Pt 2):S50-5.